Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- 230 MSs of Mediceo Begin to Work as ARs for Sawai
July 4, 2012
- COPD Treatment Oxis Approved, to Be Marketed by Meiji Seika Pharma: AZ
July 4, 2012
- Taisho Makes Tokuhon Wholly Owned Subsidiary; Expanding Business in Topical, Adhesive Agents
July 4, 2012
- Over 60% of Meiji Seika Pharma’s Generics Have Top 3 Market Share: GM Umeki
July 3, 2012
- Nippon Kayaku in Final Preparatory Stage for NK105 PIII Trials: Managing Director Suzuki
July 3, 2012
- Japan’s 5th DPP-4 Inhibitor Tenelia Approved: MTPC
July 3, 2012
- Otsuka, Kyowa Kirin Announce Strategic Alliance in Fields of Diabetes, Oncology
July 2, 2012
- Astellas Receives Approval for Prostate Cancer Treatment Gonax
July 2, 2012
- Toyama Chemical, Eisai Receive Approval for Anti-Rheumatic Treatment, to Market under 2 Brands
July 2, 2012
- Takeda Initiates International PIII Trial of Velcade Successor
July 2, 2012
- Mirabegron Approved in the US: Astellas
July 2, 2012
- Anti-Obesity Agent Belviq Approved in US, to Be Launched in Jan. 2013: Eisai
July 2, 2012
- Merck Serono No. 1 in Infertility Treatment Market through Ninkatsu Image Strategy
July 2, 2012
- M3, Mediscience, MIC Medical Consider Capital, Operational Alliance to Establish 650 CRAs Structure
June 29, 2012
- Teva Pharma to Streamline Overlapping Products in 3 years: President Shimada
June 29, 2012
- Bayer Yakuhin to Transfer 3 Established Products to FFP
June 29, 2012
- NDA Filed for Gout Treatment Topiroxostat: Fuji Yakuhin, Sanwa Kagaku
June 29, 2012
- FDA Accepts NDA for Ospemifene for VVA: Shionogi
June 29, 2012
- AnGes MG Obtains Exclusive Rights for Vaccine for Precancerous Condition of the Cervix in China
June 28, 2012
- Takeda Ranked No. 1 in Medical Category for 5th Year in a Row: Popularity Rankings for Career Change
June 28, 2012
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…